Ask AI
ProCE Banner Activity

ClinicalThought Expert Office Hours Forum: Elevating CLL/SLL Management 

Clinical Thought

Experts answer your questions related to the program, “Elevating CLL/SLL Management to Align Community Practice With Clinical Guidelines, Evidence-Based Data, and Shared Decisions.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.

Released: March 12, 2026

Review Activity

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for oncologists, hematologists, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and other healthcare professionals who care for patients with CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select first-line therapies for patients with treatment-naïve CLL/SLL considering available evidence, expert consensus and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration of treatment (continuous vs. fixed duration), and patient preferences

  • Establish individualized treatment plans for patients with relapsed/refractory CLL/SLL based on optimal sequencing strategies recommended in the NCCN Guidelines (eg, assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for treatment)

  • Integrate newer therapeutic agents and regimens for the treatment of CLL/SLL in clinical practice in accordance with NCCN Guidelines and recent clinical trial data 

  • Employ shared decision-making (SDM) strategies in clinical practice to foster treatment adherence and persistence, and optimize care outcomes in patients with CLL/SLL

Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou, Foresight Diagnostics, Genentech, Johnson & Johnson, Lilly, Miltenyi, Novartis, Roche; researcher: Allogene, Bristol Myers Squibb, Cellectis, Genentech, Merck, Mustang Bio, Regeneron, Seagen, Takeda.

Jennifer Woyach, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Genentech, Johnson & Johnson, Loxo/Lilly, Merck, Newave, Schrödinger.